We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Analysis of the Cytomegalovirus Proteome Reveals Unanticipated Complexity

By LabMedica International staff writers
Posted on 05 Dec 2012
Advanced genomic and proteomic analysis techniques have been used for an in-depth study of the proteome of human Cytomegalovirus (HCMV), an incredibly successful pathogen that infects nearly everyone.

The huge 240,000 base pair HCMV genome was sequenced more than 20 years ago, but the viral proteome (the proteins encode by those genes) has not been studied in a comprehensive fashion. More...


Investigators at the University of California, San Francisco (USA) have now obtained much of the missing proteomic data. They used state-of-the-art ribosome profiling and transcript analysis linked to mass spectrometry to experimentally define the HCMV translation products (proteins) and follow their temporal expression. In translation, messenger RNA (mRNA) produced by transcription is decoded by the ribosomes to produce specific polypeptides that will later fold into active proteins.

Ribosome profiling is a technique that uses mRNA to determine what proteins are being translated. It produces a “global snapshot” of all the ribosomes active in the cell at a particular moment. Consequently, this enables researchers to identify the location of translation start sites, their distribution, and the speed of the translating ribosomes. Ribosome profiling derived from the old discovery that the mRNA within a ribosome can be isolated through the use of nucleases that degrade unprotected mRNA regions. This technique analyzes the ratio of multiple specific mRNAs to proteins being synthesized, to provide insight into global gene expression.

Results published in the November 23, 2012, issue of the journal Science revealed hundreds of previously unidentified open reading frames (sites of protein translation), a fraction of which were confirmed by means of mass spectrometry. Many of these open reading frames were found to encode for exceptionally short protein sequences (fewer than 100 amino acids), and some of the newly identified open reading frames were sequestered inside other open reading frames.

These results unveiled an unanticipated complexity to the HCMV coding capacity and illustrated the role of the regulated use of alternative transcript start sites in enabling tight temporal control of HCMV protein expression and allowing multiple distinct polypeptides to be generated from a single genomic locus.

"The genome of a virus is just a starting point," said senior author Dr. Jonathan Weissman, professor of cellular and molecular pharmacology and of biochemistry and biophysics at the University of California, San Francisco. "Understanding what proteins are encoded by that genome allows us to start thinking about what the virus does and how we can interfere with it… Each of the proteins we have identified has the potential to tell us how this virus is manipulating its host cell."

Related Links:
University of California, San Francisco


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Immunoassay Analyzer
Procise DX
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.